PERSPECTA

News from every angle

← Back to headlines

Astellas Begins Phase 3 Trial for Gastric Cancer Drug ASP2138

Astellas has dosed its first patient in a Phase 3 study for ASP2138, a drug targeting CLDN18.2-positive and HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. This marks a significant step in the drug's development for gastric cancer treatment.

25 Aug, 00:23 — 25 Aug, 00:23
PostShare

Sources

Showing 1 of 2 sources
morningstar8h ago

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma - Morningstar

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma  Morningstar

Read full article →

Coverage Timeline

First report: morningstar · 25 Aug, 00:23Full coverage: 2 · 7hWindow: 7h
Left-leaningCenterRight-leaning
morningstar25 Aug, 00:23First to report

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma - Morningstar

7h later
investing-com25 Aug, 07:00Latest update

Senhwa completes enrollment in phase 1b cancer drug trial

Related Stories

German Economy Grows Stronger Than Expected in Q2

20m ago

Alibaba Shares Fall After $10.3 Billion Offering Confirms Investor Concerns

30m ago

Object 1 Launches Sky Level 1, Expanding JVC Residential Portfolio

37m ago

Japan's Only High-Speed Trader Moves to Singapore Citing Tax Rates

38m ago